NeuroOne Medical Technologies financials
$1.09−16.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 |
|---|---|---|---|---|---|
| Revenue | $12.1M | $3.5M | $2.0M | $2.1M | $243.0K |
| Gross profit | $8.1M | $1.1M | $456.5K | $1.9M | -$32.9K |
| Gross margin | 67.3% | 31.3% | 23.4% | 88.6% | −13.6% |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M | -$10.2M |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | -$9.9M |
| Net margin | −29.8% | −356.7% | −607.4% | −471.7% | −4094.6% |
| Diluted EPS | $-3.24 | $-16.56 | $-23.40 | $-22.68 | $-33.48 |
| EBITDA | -$4.0M | -$11.6M | -$11.8M | -$9.9M | -$10.1M |
| Operating cash flow | -$2.8M | -$11.0M | -$12.9M | -$7.5M | -$8.6M |
| Free cash flow | -$2.9M | -$11.1M | -$13.3M | -$7.8M | -$8.7M |
| Diluted shares | 1.1M | 0.7M | 0.5M | 0.4M | 0.3M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.6M | $1.5M | $5.3M | $8.2M | $6.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $3.0M | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $10.8M | $5.4M | $8.1M | $12.8M | $7.9M |
| Total liabilities | $3.7M | $4.5M | $1.8M | $3.2M | $1.4M |
| Shareholders' equity | $7.1M | $822.0K | $6.2M | $9.6M | $6.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology